Prime Medicine (PRME) Share-based Compensation (2021 - 2026)

Prime Medicine has reported Share-based Compensation for 6 years, with the latest figure at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 18.25% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $28.2 million (up 6.37% YoY), and the FY2025 full-year result was $29.3 million, up 12.28% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.6 million, up from $4.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $12.7 million in Q3 2025, with the low at $1.1 million in Q1 2022.
• Historically, Share-based Compensation has averaged $4.7 million across 5 years, with a median of $4.5 million in 2025.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 209.88% — and 2025, when it declined 24.0%.
• Prime Medicine's Share-based Compensation stood at $2.6 million in 2022, then soared by 72.07% to $4.4 million in 2023, then surged by 34.14% to $5.9 million in 2024, then dropped by 24.0% to $4.5 million in 2025, then grew by 2.86% to $4.6 million in 2026.
• The last three Share-based Compensation figures came in at $4.6 million (Q1 2026), $4.5 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.